Fig. 2

The susceptibility of DIPG cells to RG7388 is TP53-dependent. A The p53 expression of HSJD-DIPG-007-NTC (TP53 wild-type) and HSJD-DIPG-007-TP53 KO lines by western blot. B Cell viability of HSJD-DIPG-007-NTC and HSJD-DIPG-007-TP53 KO lines measured after three days of RG7388 treatment. Relative viabilities were calculated by normalizing luminescence values for each treatment condition to DMSO treated wells. C The viabilities of HSJD-DIPG-007-NTC line treated with DMSO, 50 nM and 100 nM RG7388 for two and four days. Relative viabilities were calculated by normalizing luminescence values for each time point to Day 0 at the same drug concentration. Mean ± SEM, n = 3 independent studies for each condition. P-values based on Two-way ANOVA. **P < 0.01. D Relative Caspase-3/7 activity after treatment with RG7388 for 24 h, normalized to DMSO treatment in HSJD-DIPG-007-NTC and HSJD-DIPG-007-TP53 KO lines. Mean ± SEM, n = 3 independent studies for each condition. P-values based on Student’s t-test. **P < 0.01. ns = non-significant. E Percentage of G1, S and G2 phases and representative images of HSJD-DIPG-007-NTC and HSJD-DIPG-007-TP53 KO treated with DMSO or RG7388 as measured by PI staining. Mean ± SEM, n = 3 independent studies for each condition. P values based on chi-squared test. ***P < 0.001. ns = non-significant